Whalesbook
HDFC Securities' senior technical and derivative analyst, Nandish Shah, has laid out specific options trading strategies for investors. Shah is advising a Nifty Bear Spread to benefit from a possible drop in the index, alongside a Bull Spread for Aurobindo Pharma, projecting an increase in its stock price. Both approaches are designed with clear limits on potential losses and gains.
Nifty Bearish Strategy
Shah's negative outlook on the Nifty index leads him to suggest a Bear Spread using May 26 expiry options. This involves buying the 23,600 Put option and selling the 23,400 Put option. The trade limits potential losses to ₹4,940 and offers a maximum profit of ₹8,060 if the Nifty finishes at or below 23,400 by expiration. The breakeven point is set at 23,524, resulting in a risk-reward ratio of 1:1.63. Shah's bearish view is based on a short build-up in Nifty Futures, a falling Put-Call Ratio from 1.24 to 1 due to call writing, and the index trading below its 200-day Exponential Moving Average (EMA). Additionally, the Nifty's short-term trend is weak, with the index closing below its 5 and 11-day EMAs.
Aurobindo Pharma Bullish Strategy
For Aurobindo Pharma, Shah has detailed a Bull Spread strategy, expecting the stock to move higher. The strategy consists of buying the May 26 expiry 1560 Call option and selling the 1600 Call option. The maximum profit for this trade is ₹14,575 if Aurobindo Pharma closes at or above 1600 on expiry. The maximum loss is capped at ₹7,425 if it closes at or below 1560. The breakeven point is calculated at ₹1573.5, offering a risk-reward ratio of 1:1.96. Shah's positive sentiment is supported by a long build-up in Aurobindo Pharma Futures, shown by an increase in open interest alongside a 2% price rise. The stock's short-term trend is strong, trading above its 5 and 20-day EMAs, and displaying a bullish higher top, higher bottom formation on daily charts with robust momentum indicators.
Indian Derivatives Market
The Indian equity derivatives market has expanded significantly, with retail investors now making up a large part of trading volumes. This growth is partly due to new weekly-expiring contracts and easier access via digital platforms. However, recent regulatory changes, including stricter position limits and higher margin requirements, have reduced India's options turnover compared to the US market. Nevertheless, Nifty options remain highly liquid and a favored instrument across various trading segments.
Analyst Viewpoint
Nandish Shah's strategy recommendations are derived from technical indicators and futures data. For Nifty, the 200-day EMA is a key factor, with the index trading below it signaling a bearish trend. For Aurobindo Pharma, the analysis highlights positive price action, EMA levels, and chart patterns, suggesting a bullish outlook. This aligns with general analyst sentiment for Aurobindo Pharma, where a consensus rating is "Buy." However, the average 12-month price target for Aurobindo Pharma indicates a potential drop from its current trading levels, pointing to a difference between short-term trading views and longer-term price expectations.
Important Risks
Both recommended strategies come with defined risks. The Nifty Bear Spread has a maximum loss of ₹4,940, and the Aurobindo Pharma Bull Spread has a maximum loss of ₹7,425. Traders should be aware of these limits and the possibility of losses if market movements do not follow the analyst's predictions. Increased regulatory oversight in India's derivatives market also introduces complexity, potentially affecting trading dynamics and liquidity.